Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-6

Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.

MSB would have had to put out an announcement if the DMC didn't recommend continuation of the trial, so I guess it is just as important to inform the market of either decision (Recommend / Not Recommended) ... maybe just accept the announcement for what it is - an update ?